Literature DB >> 18472943

Changes and Relationship of PAF and TNF in Rats with Myocardial Ischaemia and Reperfusion Injury.

Y L Han1, S H Li, Q Y Zheng, H B Wang, G Y Zhang, Z G Wu, S C Chen.   

Abstract

IN THIS STUDY IT IS REPORTED THAT: (1) the levels of blood platelet-activating factor and serum tumour necrosis factor significantly increased after coronary ligation and reperfusion, compared with sham-ligated controls, in an anaesthetized rat model; (2) compared with vehicle controls, pretreatment with the PAF antagonist BN 50739 (10 mg/kg, i.v.) produced significant decreases in infarct size (from 29.6 +/- 4.0% to 22.4 +/- 2.1%, p < 0.05 after 3 h ligation, and from 28.5 +/- 9.5% to 10.5 +/- 4.5%, p < 0.01 after 4 h reperfusion) and the level of serum TNF (from 10.4 +/- 7.7 U/ml to 3.9 +/- 4.8 U/ml, p < 0.05); and (3) a significan positive correlation was found between the level of blood PAF or serum TNF and infarct size. The present results indicate that PAF and TNF may be important mediators involved in myocardial ischaemia and reperfusion injury, and that PAF antagonists may exert a protective effect on ischaemic or reperfused myocardium by inhibiting the interaction of PAF and TNF.

Entities:  

Year:  1994        PMID: 18472943      PMCID: PMC2367036          DOI: 10.1155/S0962935194000281

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  12 in total

Review 1.  Role of cytokines and platelet-activating factor in microvascular immune injury.

Authors:  P Braquet; D Hosford; M Braquet; R Bourgain; F Bussolino
Journal:  Int Arch Allergy Appl Immunol       Date:  1989

2.  Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart.

Authors:  G Montrucchio; G Alloatti; F Mariano; R de Paulis; A Comino; G Emanuelli; G Camussi
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

Review 3.  PAF/cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection.

Authors:  P Braquet; M Paubert-Braquet; R H Bourgain; F Bussolino; D Hosford
Journal:  J Lipid Mediat       Date:  1989 Mar-Apr

4.  Granulocytes, platelet-activating factor, and myocardial injury.

Authors:  R Joseph; K M Welch
Journal:  Circulation       Date:  1989-06       Impact factor: 29.690

Review 5.  Models for the study of arrhythmias in myocardial ischaemia and infarction: the use of the rat.

Authors:  M J Curtis; B A Macleod; M J Walker
Journal:  J Mol Cell Cardiol       Date:  1987-04       Impact factor: 5.000

Review 6.  Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical implications (Part I).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

7.  Tumor necrosis factor primes the effects of platelet-activating factor on rat vascular permeability.

Authors:  M G Sirois; G E Plante; P Braquet; P Sirois
Journal:  J Lipid Mediat       Date:  1990

8.  Mechanisms of the cardioprotective actions of WEB-2170, bepafant, a platelet activating factor antagonist, in myocardial ischemia and reperfusion.

Authors:  X L Ma; A S Weyrich; S Krantz; A M Lefer
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

9.  Production and release of platelet-activating factor by the injured heart-muscle cell (cardiomyocyte).

Authors:  D R Janero; C Burghardt
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1990-02

10.  Production and characterization of monoclonal antibodies to human tumor necrosis factor.

Authors:  M Hirai; N Okamura; Y Terano; M Tsujimoto; H Nakazato
Journal:  J Immunol Methods       Date:  1987-01-26       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.